• 1. Synthesis and biological evaluation of lipid-like 5-(2-hydroxyethyl)-4-methyl-1,3-thiazole derivatives as potential anticancer and antimicrobial agents
  Alla Zablotskaya,Izolda Segal,Athina Geronikaki,Galina Kazachonokh,Yuris Popelis,Irina Shestakova,Vizma Nikolajeva,Daina Eze Med. Chem. Commun. 2015 6 1464

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles 4,5-disubstituted thiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles 4,5-disubstituted thiazoles

Introduction to 1,12-Bis(4-methyl-5-(2-hydroxyethyl)thiazol-3-ium-3-yldodecanedibromide) (CAS No. 321915-72-4)

1,12-Bis(4-methyl-5-(2-hydroxyethyl)thiazol-3-ium-3-yldodecanedibromide), identified by its CAS number 321915-72-4, is a sophisticated chemical compound that has garnered significant attention in the field of pharmaceutical research and biotechnology. This compound belongs to a class of molecules known for their unique structural and functional properties, making it a subject of extensive study in drug discovery and molecular medicine. The presence of multiple functional groups, including thiazole moieties and bromine substituents, endows this molecule with distinct chemical reactivity and potential biological activity.

The thiazole ring is a prominent feature in this compound, playing a crucial role in its interactions with biological targets. Thiazole derivatives are well-documented for their antimicrobial, antifungal, and anti-inflammatory properties. In particular, the 4-methyl-5-(2-hydroxyethyl)thiazol-3-ium moiety introduces a positively charged nitrogen atom, which can facilitate interactions with negatively charged residues on protein surfaces. This cationic nature enhances the compound's solubility in aqueous environments and its ability to cross cell membranes, thereby improving bioavailability.

The dodecanedibromide component of the molecule contributes to its hydrophobicity, creating a balance between hydrophilic and hydrophobic regions. This amphiphilic characteristic is particularly valuable in drug design, as it allows the compound to interact effectively with both aqueous and lipid-based environments within biological systems. The bromine atoms also serve as handles for further chemical modifications, enabling researchers to tailor the molecule's properties for specific applications.

Recent advancements in computational chemistry have enabled more precise predictions of the biological activity of 1,12-Bis(4-methyl-5-(2-hydroxyethyl)thiazol-3-ium-3-yldodecanedibromide). Molecular docking studies have revealed potential binding interactions with various therapeutic targets, including enzymes and receptors implicated in metabolic disorders and infectious diseases. These virtual screening approaches have accelerated the identification of lead compounds for further experimental validation.

In vitro studies have begun to elucidate the mechanistic aspects of this compound's action. Initial experiments suggest that it may interfere with essential cellular processes by inhibiting key enzymes or disrupting protein-protein interactions. The hydroxyethyl group attached to the thiazole ring appears to modulate the compound's reactivity, potentially influencing its binding affinity and duration of action. Further investigation into these structural features could provide insights into optimizing its pharmacological profile.

The synthesis of 1,12-Bis(4-methyl-5-(2-hydroxyethyl)thiazol-3-ium-3-yldodecanedibromide) presents unique challenges due to its complex architecture. Multi-step synthetic routes involving functional group transformations such as alkylation, bromination, and cyclization are typically employed. Advances in synthetic methodologies have improved the efficiency and scalability of production, making it feasible to conduct large-scale screening programs for drug discovery purposes.

The potential applications of this compound extend beyond traditional pharmaceuticals. Its unique properties make it a promising candidate for use in biotechnology, particularly in the development of novel materials with tailored functionalities. For instance, its ability to form stable complexes with other biomolecules could be exploited in drug delivery systems or biosensors.

Regulatory considerations are an essential aspect of advancing compounds like 1,12-Bis(4-methyl-5-(2-hydroxyethyl)thiazol-3-ium-3-yldodecanedibromide) into clinical use. Compliance with Good Manufacturing Practices (GMP) ensures that synthesized materials meet stringent quality standards required for pharmaceutical applications. Additionally, preclinical safety studies are necessary to assess potential toxicity profiles before human trials can commence.

The integration of artificial intelligence (AI) into drug discovery workflows has significantly impacted the development pipeline for compounds such as this one. AI-driven platforms can predict physicochemical properties and assess drug-likeness more rapidly than traditional methods. These tools have helped identify promising candidates like 1,12-Bis(4-methyl-5-(2-hydroxyethyl)thiazol-3-ium-3-yldodecanedibromide) that warrant further investigation.

Ethical considerations also play a role in pharmaceutical research involving such compounds. Ensuring equitable access to promising treatments and addressing environmental impact concerns are integral parts of responsible innovation in this field.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)